462
H. Jin
247. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf
JL, Gill SC, Bendele RA (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus
monkeys. Pharm Res 17(12):1503–1510. https://doi.org/10.1023/a:1007657109012
248. Drolet DW, Green LS, Gold L, Janjic N (2016) Fit for the eye: aptamers in ocular disorders.
Nucl Acid Ther 26(3):127–146. https://doi.org/10.1089/nat.2015.0573
249. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR,
Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington
RA, Tonkens RM, Becker RC, Rusconi CP (2008) Phase 1b randomized study of antidotecontrolled modulation of factor IXa activity in patients with stable coronary artery disease.
Circulation 117(22):2865–2874. https://doi.org/10.1161/circulationaha.107.745687
250. Moreno A, Pitoc GA, Ganson NJ, Layzer JM, Hershfield MS, Tarantal AF, Sullenger BA
(2019) Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers. Cell
Chem Biol 26(5):634–644.e633. https://doi.org/10.1016/j.chembiol.2019.02.001
H. Jin
247. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf
JL, Gill SC, Bendele RA (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus
monkeys. Pharm Res 17(12):1503–1510. https://doi.org/10.1023/a:1007657109012
248. Drolet DW, Green LS, Gold L, Janjic N (2016) Fit for the eye: aptamers in ocular disorders.
Nucl Acid Ther 26(3):127–146. https://doi.org/10.1089/nat.2015.0573
249. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR,
Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington
RA, Tonkens RM, Becker RC, Rusconi CP (2008) Phase 1b randomized study of antidotecontrolled modulation of factor IXa activity in patients with stable coronary artery disease.
Circulation 117(22):2865–2874. https://doi.org/10.1161/circulationaha.107.745687
250. Moreno A, Pitoc GA, Ganson NJ, Layzer JM, Hershfield MS, Tarantal AF, Sullenger BA
(2019) Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers. Cell
Chem Biol 26(5):634–644.e633. https://doi.org/10.1016/j.chembiol.2019.02.001
Précédent